Páris Sidiropoulos

641 total citations
17 papers, 468 citations indexed

About

Páris Sidiropoulos is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Páris Sidiropoulos has authored 17 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in Páris Sidiropoulos's work include Otitis Media and Relapsing Polychondritis (5 papers), Vasculitis and related conditions (5 papers) and Hereditary Neurological Disorders (4 papers). Páris Sidiropoulos is often cited by papers focused on Otitis Media and Relapsing Polychondritis (5 papers), Vasculitis and related conditions (5 papers) and Hereditary Neurological Disorders (4 papers). Páris Sidiropoulos collaborates with scholars based in Switzerland, United States and Germany. Páris Sidiropoulos's co-authors include Ueli Suter, Pierre Charbord, Christian Jørgensen, Claudia Stendel, Jochen Ringe, Stéphane Roche, Thomas Häupl, Sylvain Lehmann, D. Boumpas and Helen Α. Papadaki and has published in prestigious journals such as Brain, PLoS Biology and Annals of the Rheumatic Diseases.

In The Last Decade

Páris Sidiropoulos

16 papers receiving 464 citations

Peers

Countries citing papers authored by Páris Sidiropoulos

Since Specialization

Citations

This map shows the geographic impact of Páris Sidiropoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Páris Sidiropoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Páris Sidiropoulos more than expected).

Fields of papers citing papers by Páris Sidiropoulos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Páris Sidiropoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Páris Sidiropoulos. The network helps show where Páris Sidiropoulos may publish in the future.

Co-authorship network of co-authors of Páris Sidiropoulos

This figure shows the co-authorship network connecting the top 25 collaborators of Páris Sidiropoulos. A scholar is included among the top collaborators of Páris Sidiropoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Páris Sidiropoulos. Páris Sidiropoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder 2021 ·Journal of the Neurological Sciences ·Alex Exuzides, Daniel Sheinson, Páris Sidiropoulos, Fabio Magrini, Shervin Gholizadeh, Andy Surinach, Lawrence J. Cook, Craig S. Meyer, Michael R. Yeaman	16
2	Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database 2021 ·Journal of Medical Economics ·Alex Exuzides, Ning Wu, Daniel Sheinson, (unknown), (unknown), Páris Sidiropoulos	3
3	Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations 2021 ·Arthritis Research & Therapy ·Sebastian Unizony, Timothy J. McCulley, Robert Spiera, Jinglan Pei, Páris Sidiropoulos, Jennie H. Best, (unknown), Andrey Pavlov, John H. Stone	41
4	The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder 2021 ·Journal of the Neurological Sciences ·Alex Exuzides, Daniel Sheinson, Páris Sidiropoulos, Shervin Gholizadeh, Fabio Magrini, Andy Surinach, Lawrence J. Cook, Craig S. Meyer, Michael R. Yeaman	8
5	Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis 2020 ·Lara D. Veeken ·Andrea Rubbert‐Roth, Daniel Aletaha, Jenny Devenport, Páris Sidiropoulos, (unknown), Michael Edwardes, Johannes W G Jacobs	11
6	Visual impairment in patients with giant cell arteritis treated with tocilizumab in real-world clinical practice 2019 ·Investigative Ophthalmology & Visual Science ·(unknown), Timothy J. McCulley, Jinglan Pei, Páris Sidiropoulos, (unknown), Jennie H. Best, John H. Stone, Sebastian Unizony	1
7	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice 2019 ·Clinical Rheumatology ·Vivian P. Bykerk, Andrew J.K. Östör, José María Álvaro‐Gracia, Karel Pavelká, Jose Andrés Román Ivorra, Michael T. Nurmohamed, (unknown), Páris Sidiropoulos, Jenny Devenport, Jean Sibilia	6
8	FRI0261 RISK FACTORS FOR TREATMENT FAILURE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE VERSUS PREDNISONE ALONE 2019 ·Annals of the Rheumatic Diseases ·Sebastian Unizony, Min Bao, Jian Han, (unknown), Páris Sidiropoulos, Jinglan Pei, John H. Stone	4
9	Schwann cells, but not Oligodendrocytes, Depend Strictly on Dynamin 2 Function 2019 ·eLife ·Daniel Gerber, Monica Ghidinelli, Elisa Tinelli, Christian Somandin, Joanne Gerber, Jorge A. Pereira, (unknown), Gianluca Figlia, Michaela Miehe, (unknown), (unknown), (unknown), Páris Sidiropoulos, Carsten Wessig, Klaus V. Toyka, Ueli Suter	27
10	274. CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE 2019 ·Lara D. Veeken ·Sebastian Unizony, Jinglan Pei, Páris Sidiropoulos, Jennie H. Best, (unknown), John H. Stone	0
11	358. RISK FACTORS FOR TREATMENT FAILURE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE VERSUS PREDNISONE ALONE 2019 ·Lara D. Veeken ·Sebastian Unizony, Min Bao, (unknown), Páris Sidiropoulos, Jinglan Pei, John H. Stone, (unknown)	2
12	Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study 2017 ·Clinical Rheumatology ·Ruediger B. Müeller, W. Graninger, Páris Sidiropoulos, (unknown), Johannes von Kempis	6
13	HDAC1/2-Dependent P0 Expression Maintains Paranodal and Nodal Integrity Independently of Myelin Stability through Interactions with Neurofascins 2015 ·PLoS Biology ·Valérie Brügger‐Verdon, Stefanie Engler, Jorge A. Pereira, Sophie Ruff, Michael Horn, Hans Welzl, Emmanuelle Münger, (unknown), Páris Sidiropoulos, Boris Egger, (unknown), Luis Filgueira, Christian Somandin, Tessa Lühmann, Maurizio D’Antonio, Teppei Yamaguchi, Patrick Matthias, Ueli Suter, Claire Jacob	30
14	Myelin is dependent on the Charcot–Marie–Tooth Type 4H disease culprit protein FRABIN/FGD4 in Schwann cells 2012 ·Brain ·Michael Horn, (unknown), Jorge A. Pereira, Páris Sidiropoulos, Christian Somandin, Hans Welzl, Claudia Stendel, Tessa Lühmann, Carsten Wessig, Klaus V. Toyka, João B. Relvas, Jan Senderek, Ueli Suter	56
15	Dynamin 2 mutations in Charcot–Marie–Tooth neuropathy highlight the importance of clathrin-mediated endocytosis in myelination 2012 ·Brain ·Páris Sidiropoulos, Michaela Miehe, Thomas Bock, Elisa Tinelli, (unknown), Rohini Kuner, Dies Meijer, Bernd Wollscheid, Axel Niemann, Ueli Suter	54
16	SH3TC2, a protein mutant in Charcot–Marie–Tooth neuropathy, links peripheral nerve myelination to endosomal recycling 2010 ·Brain ·Claudia Stendel, Andreas Roos, H. O. Kleine, Estelle Arnaud, (unknown), Páris Sidiropoulos, Jennifer Zenker, Fanny Schüpfer, Ute Lehmann, Radoslaw M. Sobota, David W. Litchfield, Bernhard Lüscher, Roman Chrast, Ueli Suter, Jan Senderek	74
17	Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis 2007 ·Annals of the Rheumatic Diseases ·(unknown), Páris Sidiropoulos, Stéphane Roche, Jochen Ringe, Sylvain Lehmann, H Kritikos, (unknown), (unknown), George D. Eliopoulos, Christian Jørgensen, Pierre Charbord, Thomas Häupl, D. Boumpas, Helen Α. Papadaki	129

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact